Overview

Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

Status:
Not yet recruiting
Trial end date:
2033-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial] is to compare in resectable stage T3-4N2 colorectal cancer. The main question it aims to answer is: whether the use of targeted therapy in combination with adjuvant chemotherapy is associated with improved disease-free survival (DFS) compared to adjuvant chemotherapy alone.
Phase:
Phase 3
Details
Lead Sponsor:
Sixth Affiliated Hospital, Sun Yat-sen University
Treatments:
Bevacizumab
Cetuximab